Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The Wnt pathway is crucial for embryonic development and tissue regeneration.
• Dysregulation of Wnt signaling, often due to mutations in key proteins, is linked to cancer development.
• Casein kinase 2 (CK2) activity has been implicated in Wnt pathway signaling, suggesting it as a potential therapeutic target.

Purpose of the Study:

• To identify a potent and selective inhibitor of CK2 for in vivo studies.
• To investigate the link between CK2 activity and Wnt pathway signaling.
• To develop a novel therapeutic strategy for Wnt-driven cancers.

Main Methods:

• Utilized a pyrazolo[1,5-a]pyrimidine scaffold to design and synthesize potential CK2 inhibitors.
• Evaluated CK2 inhibitory activity and selectivity against other kinases.
• Assessed Wnt pathway inhibition in DLD-1 cancer cells.
• Conducted pharmacokinetic and efficacy studies in preclinical cancer models (HCT-116 and SW-620 xenografts).

Main Results:

• Identified compound 7h, a potent CK2 inhibitor with picomolar affinity and high selectivity.
• Compound 7h demonstrated significant inhibition of Wnt pathway signaling in DLD-1 cells (IC50 = 50 nM).
• Compound 7h possesses suitable physicochemical properties for intravenous formulation and exhibits favorable pharmacokinetics.
• Demonstrated potent anti-tumor activity as a monotherapy in HCT-116 and SW-620 xenograft models.

Conclusions:

• Compound 7h is a highly potent and selective CK2 inhibitor with demonstrated Wnt pathway inhibitory activity.
• Compound 7h shows promising preclinical efficacy as a monotherapy for Wnt-driven cancers.
• The favorable pharmacokinetic profile and in vivo activity support further development of compound 7h for cancer treatment.